Claims for Patent: 9,981,013

Summary for Patent: 9,981,013

Title:	Use of AVE0010 for the treatment of diabetes mellitus type 2
Abstract:	The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
Inventor(s):	Boka; Gabor (Paris, FR), Miossec; Patrick (Paris, FR), Silvestre; Louise (Paris, FR)
Assignee:	SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:	15/237,285
Patent Claims:	1. A method of improving glycemic control in a patient with type 2 diabetes mellitus comprising: administering a dose of 10 .mu.g lixisenatide to the patient once daily for 14 days, and administering a dose of 20 .mu.g lixisenatide to the patient once daily starting on day 15 of lixisenatide treatment. 2. The method of claim 1, wherein the patient is an adult. 3. The method of claim 1, wherein the patient has an HbA1c value of about 7% to about 10%. 4. The method of claim 1, wherein the patient is not currently receiving treatment with antidiabetic agents. 5. The method of claim 1, wherein the patient is inadequately controlled on the patient's current antidiabetic treatment. 6. The method of claim 5, wherein the patient's current antidiabetic treatment does not include an antidiabetic agent. 7. The method of claim 1, wherein the lixisenatide is administered as a pharmaceutical composition comprising lixisenatide, methionine, a suitable preservative, and a tonicity agent. 8. The method of claim 1, wherein the lixisenatide is administered as a pharmaceutical composition comprising lixisenatide, methionine, m-cresol, and glycerol.